CeleCor Therapeutics

CeleCor Therapeutics

Developing, RUC-4, a novel  small molecule inhibitor of the platelet αIIbβ3 receptor, designed to be easily administered subcutaneously by auto-injector to facilitate its use as the  first point of contact treatment for STEMI

Area of focus: 
Other
Commencement date: 
05/16/2017

Share